Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
P resistance was demonstrated by pyronidine tetraphosphate (24 h). The IC50 value for Plasmodium falciparum activity is 1.53-3.94 nM [1].
|
---|---|
ln Vivo |
In mice infected with Echinococcus granulosus, pyronaridine tetraphosphate (57 mg/kg, orally, once day for 30 days) decreases the parasite load [2]. In secondary-infected (cyst) mice, napranidine tetraphosphate (57 mg/kg, intraperitoneally given once daily for 3 days) lowers the parasite load [2]. Male ICR mice had higher liver exposure to pyronidine (57 mg/kg, i.p., single dose) tetraphosphate than plasma [2].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: Plasmodium falciparum: 3D7, K1, VS1, FCB, TM90C2a, FCR3 Tested Concentrations: ~0-7 nM Incubation Duration: 24 hrs (hours) Experimental Results: Anti-P. falciparum is shown. Plasmodium falciparum activity, the average IC50 values are 2.31 nM, 3.94 nM, 1.63 nM, 1.53 nM, 2.51 nM, 2.21 nM respectively. |
Animal Protocol |
Animal/Disease Models: Mouse model of Echinococcus granulosus infection[2]
Doses: 57 mg/kg Route of Administration: Orally, one time/day for 30 days. Experimental Results: The wet weight of the parasite was diminished by 42.4%, and Echinococcus granulosus was killed. Secondary tapeworm infection (cyst) 90.7% SS. |
References |
[1]. Vivas L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008 Mar;105(3):222-8.
[2]. Jun Li, et al. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections. EBioMedicine. 2020 Apr;54:102711. |
Molecular Formula |
C29H44CLN5O18P4
|
---|---|
Molecular Weight |
910.03
|
Exact Mass |
909.132
|
Elemental Analysis |
C, 38.28; H, 4.87; Cl, 3.90; N, 7.70; O, 31.65; P, 13.61
|
CAS # |
76748-86-2
|
Related CAS # |
Pyronaridine;74847-35-1;Pyronaridine-d4 tetraphosphate;1186026-25-4
|
PubChem CID |
156867
|
Appearance |
Solid powder
|
Density |
1.357g/cm3
|
Boiling Point |
657.2ºC at 760 mmHg
|
Melting Point |
233-236° (dec)
|
Flash Point |
351.3ºC
|
Index of Refraction |
1.72
|
LogP |
2.32
|
Hydrogen Bond Donor Count |
14
|
Hydrogen Bond Acceptor Count |
23
|
Rotatable Bond Count |
7
|
Heavy Atom Count |
57
|
Complexity |
757
|
Defined Atom Stereocenter Count |
0
|
SMILES |
OC1=C(CN2CCCC2)C=C(NC3=C4N=C(OC)C=CC4=NC5=CC(Cl)=CC=C53)C=C1CN6CCCC6.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O
|
InChi Key |
XBTXQAIQZLVVRR-IAIGYFSYSA-N
|
InChi Code |
InChI=1S/C9H13N2O9P.C5H4O2/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)186-5-3-1-2-4-7-5/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H2,16,17,18)1-4H/t4-,6-,7-,8-/m1./s1
|
Chemical Name |
Pyronaridine phosphate
|
Synonyms |
Pyronaridine Tetraphosphate
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~25 mg/mL (~27.47 mM)
DMSO : ~12.5 mg/mL (~13.74 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (54.94 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.0989 mL | 5.4943 mL | 10.9886 mL | |
5 mM | 0.2198 mL | 1.0989 mL | 2.1977 mL | |
10 mM | 0.1099 mL | 0.5494 mL | 1.0989 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05160363 | COMPLETEDWITH RESULTS | Drug: Pyronaridine Tetraphosphate Drug: Piperaquine tetraphosphate Drug: Placebo |
Healthy | Medicines for Malaria Venture | 2022-02-14 | Phase 1 |
NCT05291390 | UNKNOWN STATUS | Drug: Pyronaridine Tetraphosphate | Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia (AML) |
Armaceutica, Inc. | 2022-11-21 | Phase 2 |
NCT05974267 | RECRUITING | Drug: M5717 60 mg Drug: Pyronaridine Drug: Atovaquone-Proguanil |
Malaria Infection | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-11-28 | Phase 2 |
NCT03814616 | UNKNOWN STATUS | Drug: Pyronaridine tetraphosphate 180mg:artesunate 60mg |
Malaria,Falciparum | Shin Poong Pharmaceutical Co. Ltd. | 2018-10-03 | Phase 2 |
NCT01594931 | COMPLETEDWITH RESULTS | Drug: pyronaridine/artesunate | Plasmodium Falciparum Malaria | Medicines for Malaria Venture | 2005-07 | Phase 2 |